Immunochemical detection of circulating oxidized high-density lipoprotein with antioxidized apolipoprotein A-I monoclonal antibody

Journal of Laboratory and Clinical Medicine

Volumn 141, Issue 6, 2003, Pages 378-384

  Nakano, Takanari ^a   Nagata, Atsuo ^a  

^a YAMASA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; IRON; MALONALDEHYDE; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ACETYLATION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOCHEMISTRY; IRON BLOOD LEVEL; PROTEIN ANALYSIS;

EID: 0038472227     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00026-X     Document Type: Article

References (21)

1. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
2. Pieters MN, Schouten D, Van Berkel TJ. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta 1994;1225:125-34.
3. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 2000;1483:217-35.
4. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83.
5. Gerrity RG. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981;103:181-90.
6. Ylä-Herttuala S. Oxidized LDL and atherogenesis. Ann N Y Acad Sci 1999;874:134-7.
7. Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem J 1996;314:739-42.
8. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 1992;89:10316-20.
9. von Eckardstein A, Walter M, Holz H, Benninghoven A, Assmann G. Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproreins A-I, C-II, and C-III. J Lipid Res 1991;32:1465-76.
10. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 2001;1531:4-46.
11. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975;65:42-9.
12. Rudel LL, Lee JA, Morris MD, Felts JM. Characterization of plasma lipoproteins separated and purified by agarose-column chromatography. Biochem J 1974;139:89-95.
13. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. J Biol Chem 1994;269:15274-9.
14. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by α-tocopherol. J Biol Chem 1998;273:6080-7.
15. de St. Groth SF, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980;35:1-21.
16. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94.
17. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-8.
18. Mercodia AB (Sweden)Direction for use of Mercodia oxidized LDL ELISA. Available from. [Accessed February 11, 2003].
19. Yoshida M, Moriwaki T, Fujita S, Katayama Y, Takagi Y, Gomi K. In vitro stability of serum lipoproteins: the effects of stabilizing agents. Seibutsu Shiryou Bunseki 2000;23:211-24.
20. Biberstine-Kinkade KJ, DeLeo FR, Epstein RI, LeRoy BA, Nauseef WM, Dinauer MC. Heme-ligating histidines in flavocytochrome b(558): identification of specific histidines in gp91(phox). J Biol Chem 2001;276:31105-12.
21. Guzik TJ, West NE, Black E, McDonald D, Ramatunga C, Pillai R, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000;102:1744-7.